ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years
Yanfei An
Matched on ORCID iD 0000-0002-1458-7442; OpenAlex author ID A5046534022. Sources: OpenAlex.
Their work
- Papers
- 3
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 17
2023: 1 paper · 2024: none · 2025: 1 paper · 2026: 1 paper
Papers 3
- Pathomics Signature for Prognosis and CA19-9 Interception in Pancreatic Ductal Adenocarcinoma: A Real-Life, Multi-Center Study. Co-author DOI 10.1002/advs.202515952↗
- Intratumoral IL-33 + CD4 + FoxP3 + regulatory T cell infiltration determines poor clinical outcomes and intensive immunoevasive contexture in patients with pan… Co-author DOI 10.1097/js9.0000000000002733↗
- Therapeutic advances targeting tumor angiogenesis in pancreatic cancer: Current dilemmas and future directions. Co-author DOI 10.1016/j.bbcan.2023.188958↗
Closest collaborators
The 17 strongest of 17 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Ning Pu · 3 shared papers, 2023–2026 · strength 0.66
- Paper Therapeutic advances targeting tumor angiogenesis in pancreatic cancer: Current dilemmas and future directions. DOI 10.1016/j.bbcan.2023.188958↗
- Paper Pathomics Signature for Prognosis and CA19-9 Interception in Pancreatic Ductal Adenocarcinoma: A Real-Life, Multi-Cente… DOI 10.1002/advs.202515952↗
- Paper Intratumoral IL-33 + CD4 + FoxP3 + regulatory T cell infiltration determines poor clinical outcomes and intensive immun… DOI 10.1097/js9.0000000000002733↗
- Wenquan Wang · 2 shared papers, 2023–2025 · strength 0.44
- Paper Therapeutic advances targeting tumor angiogenesis in pancreatic cancer: Current dilemmas and future directions. DOI 10.1016/j.bbcan.2023.188958↗
- Paper Intratumoral IL-33 + CD4 + FoxP3 + regulatory T cell infiltration determines poor clinical outcomes and intensive immun… DOI 10.1097/js9.0000000000002733↗
- Hanlin Yin · 2 shared papers, 2025–2026 · strength 0.42
- Paper Pathomics Signature for Prognosis and CA19-9 Interception in Pancreatic Ductal Adenocarcinoma: A Real-Life, Multi-Cente… DOI 10.1002/advs.202515952↗
- Paper Intratumoral IL-33 + CD4 + FoxP3 + regulatory T cell infiltration determines poor clinical outcomes and intensive immun… DOI 10.1097/js9.0000000000002733↗
- Qiangda Chen · 2 shared papers, 2025–2026 · strength 0.42
- Paper Pathomics Signature for Prognosis and CA19-9 Interception in Pancreatic Ductal Adenocarcinoma: A Real-Life, Multi-Cente… DOI 10.1002/advs.202515952↗
- Paper Intratumoral IL-33 + CD4 + FoxP3 + regulatory T cell infiltration determines poor clinical outcomes and intensive immun… DOI 10.1097/js9.0000000000002733↗
- Jun Yu · 2 shared papers, 2025–2026 · strength 0.42
- Paper Pathomics Signature for Prognosis and CA19-9 Interception in Pancreatic Ductal Adenocarcinoma: A Real-Life, Multi-Cente… DOI 10.1002/advs.202515952↗
- Paper Intratumoral IL-33 + CD4 + FoxP3 + regulatory T cell infiltration determines poor clinical outcomes and intensive immun… DOI 10.1097/js9.0000000000002733↗
- Taochen He · 2 shared papers, 2025–2026 · strength 0.42
- Paper Pathomics Signature for Prognosis and CA19-9 Interception in Pancreatic Ductal Adenocarcinoma: A Real-Life, Multi-Cente… DOI 10.1002/advs.202515952↗
- Paper Intratumoral IL-33 + CD4 + FoxP3 + regulatory T cell infiltration determines poor clinical outcomes and intensive immun… DOI 10.1097/js9.0000000000002733↗
- Wenhui Lou · 2 shared papers, 2025–2026 · strength 0.42
- Paper Pathomics Signature for Prognosis and CA19-9 Interception in Pancreatic Ductal Adenocarcinoma: A Real-Life, Multi-Cente… DOI 10.1002/advs.202515952↗
- Paper Intratumoral IL-33 + CD4 + FoxP3 + regulatory T cell infiltration determines poor clinical outcomes and intensive immun… DOI 10.1097/js9.0000000000002733↗
- Liang Liu · 1 shared paper, 2023 · strength 0.24
- Yiping Zou · 1 shared paper, 2026 · strength 0.22
- Jihui Hao · 1 shared paper, 2026 · strength 0.22
- Zhihang Xu · 1 shared paper, 2025 · strength 0.20
- Liang Liu · 1 shared paper, 2025 · strength 0.20
- Yaolin Xu · 1 shared paper, 2025 · strength 0.20
- Jiande Han · 1 shared paper, 2025 · strength 0.20
- Haibo Wang · 1 shared paper, 2025 · strength 0.20
- Yun Jin · 1 shared paper, 2025 · strength 0.20
- Wenchuan Wu · 1 shared paper, 2025 · strength 0.20
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.